Skip Navigation

Current Faculty

Kenneth Tew, PhD, DSc

Tew PictureProfessor and Chairman
John C. West Chair of Cancer Research

Program Leader - Developmental Cancer Therapeutics Program
Hollings Cancer Center

1976         Ph.D.,
University of London
1995         D.Sc.,
Institute of Cancer Research

Contact Info
Tel: 843-792-2514
Fax: 843-792-2475
Office: DD413 & BSB 358

Research Interests

Cancer Drug Development

The development of novel drugs remains a high priority in the successful therapeutic management of cancer. We have applied our accumulated knowledge of glutathione and glutathione S-transferases to the design and testing of new drugs that target glutathione pathways. In collaboration with industrial sector colleagues, a GST activated prodrug is now in late stage clinical testing. In addition, a small molecule peptidomimetic myeloproliferative agent is presently in early clinical testing in myelodysplastic syndrome. We continue to work on the molecular and biochemical mechanisms of these drugs and to elucidate cellular pathways that impact upon drug response and resistance.

Other efforts focus upon the elucidation of the function of a novel human membrane transporter, ABCA2. Continuing studies suggest that cholesterol trafficking may be controlled by this transporter. Its role in human disease states may serve as a prelude to targeting it for therapeutic intervention.

ABCA2 Knockout Mouse Movies

Recent Publications | Additional Publications

1. Tew, K.D. and Townsend, D. M. Regulatory functions of GSTP unrelated to detoxification. Drug Metabolism Reviews: in 43: 179-193, 2011.

2. Tew, K.D. and Townsend, D.M. Redox Platforms in Cancer Drug Discovery and Development. Current opinions in Chemical Biology: 15: 156-161 2011.

3. Xiong, Y., Uys, J. D., Tew, K.D. and Townsend, D.M. S-glutathionylation: from molecular mechanisms to health outcomes. Antioxidants and Redox Signaling: July: pp 233-270, 2011.

4. Tew, K.D., Manevich, Y., Grek, C.L., Xiong, Y., Uys J. and Townsend, D. M.  The Role of Glutathione S-transferase P in signaling pathways and S-glutathionylation in Cancer. Free Radical Biology Medicine  51: 299-313, 2011.

5: Townsend, D.M., Manevich, Y., He, L., Hutchens, S. and Tew, K.D. Nitrosative-stress induced S-glutathionylation of PDI leads to activation of the unfolded protein response. Cancer Research, 69: 7626-7634, 2009.

6: Townsend D.M., He, L., Hutchens, S., Pazoles C.J. and Tew, K.D. Novel role for glutathione S-transferase pi. Regulator of protein S-Glutathionylation following oxidative and nitrosative stress.   J. Biol. Chem. 284: 436-445, 2009.

7: Hutchens, S., Manevich, Y., He, L., Tew, K.D. and Townsend, D. M. Cellular Resistance to a Nitric Oxide Releasing Glutathione S-Transferase P-activated Prodrug. Investigational New Drugs, Cover Date: 2010-03-15: Springer Netherlands, Issn: 0167-6997, 2010.

8. Manevich, Y., Townsend, D. M., Hutchens, S. and Tew, K.D. Diazeniumdiolate Mediated Nitrosative Stress Alters Nitric Oxide Homeostasis Through Intracellular Calcium and S-Glutathionylation of Nitric Oxide Synthetase. PLoS ONE, Vol. 5, Issue 11, pages e14151; Epub date 2010.


© 2012  Medical University of South Carolina | Disclaimer